Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 03 August, 2010

Summit Corporation PLC

Research Update

Summit Corporation plc
("Summit" or "the Company")


Oxford, UK, 3 August 2010, Summit Corporation plc (AIM: SUMM), a UK drug
discovery Company with an innovative Seglin(TM) technology platform and a
portfolio of partner funded programmes, has received notification from one of
its partners, BioMarin Pharmaceuticals Inc. ('BioMarin'), of their intention to
discontinue development of BMN-195, for the treatment of Duchenne muscular
dystrophy ('DMD').  BMN-195 is a non-Seglin small molecule that was licensed to
BioMarin in 2008.

Summit remains a well-funded business with BioMarin's decision having no impact
on current cash life, which is expected to fund the further development of its
Seglin(TM) technology platform until December 2011.  The Board remains confident
of its ability to deliver a number of new commercial deals from its innovative
Seglin(TM) technology platform during this funding window.

DMD Phase I Clinical Trial Results & Future Plans
Following completion of the Phase I clinical trial in healthy volunteers,
BioMarin have cited pharmaceutical and pharmacokinetic challenges related to
plasma concentrations of BMN-195 as the reason for discontinuing its
development, and giving notice to terminate the agreement between the two
companies.  No safety issues or adverse events were reported by BioMarin.  Under
the terms of the agreement, BMN-195, and all associated assets and IP that were
assigned to BioMarin, will now transfer back to Summit.

Summit remains committed to working in DMD and believes the use of an
appropriate formulation of this compound can continue its development into a
viable medicine.  Summit will therefore seek a new partner to financially
support the continued development of this compound.

Steven Lee, PhD, Chief Executive Officer of Summit commented:
"This is disappointing for everyone connected with this programme, especially
the DMD patients and families, as BioMarin's decision means the advancement of
this potential treatment option will be delayed.  However, Summit remains
committed to working in DMD and we are investigating partnering opportunities to
continue the development of this compound as it is our belief that an
appropriate formulation of it can produce a viable medicine.

"Importantly, Summit's strategy of focussing on its Seglin drug discovery
technology and targeting multiple early-stage deals, means that we have a number
of opportunities to achieve commercial success within the current cash life of
the business."

                                    - END -

For more information, please contact:


 Steven Lee, PhD

 Richard Pye, PhD                             Tel: +44 (0)1235 443939

 Singer Capital Markets (Nominated Adviser)

 Shaun Dobson / Claes Spång                   Tel: +44 (0)20 3205 7500

 Peckwater PR

 Tarquin  Edwards                             Tel: +44 (0)7879 458 364
                                              [email protected]

About Summit

Summit is an Oxford, UK based drug discovery company with an innovative
technology platform called Seglins(TM) for the discovery of new medicines, a
portfolio of partner funded drug programmes and a commercial strategy of signing
multiple early-stage deals

Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches.  Summit's
internal research is currently focussed in the high value therapy areas of type
II diabetes and infectious diseases and the Company will further exploit the
technology's wider potential through strategic alliances.  Summit's portfolio of
partner funded drug programmes require no further investment from the Company
but have the potential to deliver future upside for the business.

Summit's commercial strategy focuses on signing multiple early-stage drug
programme and technology platform deals that generate upfront cash, remove
development costs and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM.  Further information is available


This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
All reproduction for further distribution is prohibited.
Source: Summit Corporation PLC via Thomson Reuters ONE


a d v e r t i s e m e n t